HAC (Russian)
RSCI (Russian)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

Early vascular aging: pathogenesis and possibilities of drug correction

DOI: https://doi.org/10.29296/25877305-2019-12-03

I. Avdeeva, Candidate of Medical Sciences; N. Burko, Candidate of Medical Sciences; O. Kvasova; T. Aryasova Penza State University

The paper describes in detail the concept of early vascular aging and deals with differences in the pathophysiological structural and functional changes in the arteries with aging as part of the body’s natural involution and with acceleration of this process. It shows the role of the prenatally incorporated program that subsequently exacerbates the influence of exogenous risk factors. The factors and diseases that accelerate the aging process are analyzed. Much attention is paid to the existing possibilities of influencing early vascular aging; the areas that can be potentially promising for further investigation are denoted.

early vascular aging
risk factors
arterial stiffness

  1. Reaven G. Role of insulin resistance in human disease // Diabetes. – 1988; 37 (12): 1595–607. DOI: 10.2337/diab.37.12.1595.
  2. Nilsson P., Lurbe E., Laurent S. The early life origins of vascular aging and cardiovascular risk: the EVA syndrome // J. Hypertens. – 2008; 26 (6): 1049–57. DOI: 10.1097/HJH.0b013e3282f82c3e.
  3. Laurent S. Defining vascular aging and cardiovascular risk // J. Hypertens. – 2012; 30: S3–8. DOI: 10.1097/HJH.0b013e328353e501.
  4. Chantler P., Lakatta E. Arterial–ventricular coupling with aging and disease // Front Physiol. – 2012; 3 (90): 1–12. DOI: 10.3389/fphys.2012.00090.
  5. Troitskaja E.A., Vel'makin S.V., Kobalava Zh.D. Kontseptsija sosudistogo vozrasta: novyj instrument otsenki serdechno-sosudistogo riska // Arterial'naja gipertenzija. – 2017; 23 (2): 160–71 [Troitskaya E.A., Velmakin S.V., Kobalava Z.D. Concept of vascular age: new tool in cardiovascular risk assessment // Arterial`naya Gipertenziya. – 2017; 23 (2): 160–71 (in Russ.)]. DOI: 10.18705/1607-419x-2017-23-2-160-171.
  6. O`Rourke M. Arterial aging: pathophysiological principles // Vasc. Med. – 2007; 12 (4): 329–41. DOI: 10.1177/1358863X07083392.
  7. Spartano N., Augustine J., Lefferts W. et al. Arterial stiffness as a noninvasive tissue biomarker of cardiac target organ demage // Current Biomarker Findings. – 2014; 2014 (4): 23–34. DOI: 10.2147/CBF.S38738.
  8. Hashimoto J., Ito S. Some mechanical aspects of arterial aging: physiological overview based on pulse wave analysis // Ther. Adv. Cardiovasc. Dis. – 2009; 3 (5): 367–78. DOI: 10.1177/1753944709338942.
  9. Kobalava Zh.D. Kotovskaja Ju.V., Moiseev V.S. Arterial'naja gipertonija. Kljuchi k diagnostike i lecheniju / M.: GEOTAR-Media; 2009, 864 s. [Kobalava Zh.D. Kotovskaya Yu.V., Moiseev V.S. Arterial’naya gipertoniya. Klyuchi k diagnostike i lecheniyu / M.: GEOTAR-Media; 2009, 864 s. (in Russ.)].
  10. Zahner G., Gruendl M., Spaulding K. et al. The association between arterial stiffness and peripheral artery disease as measured by radial artery tonometry // J. Vasc Surg. – 2017; 66 (5): 1518–26. DOI: 10.1016/j.jvs.2017.06.068.
  11. Muiesan M., Salvetti M., Rizzoni D. et al. Pulsatile hemodinamics and microcirculation: evidence for a close relationship in hypertensive patients // Hypertension. – 2013; 61 (1): 130–6. DOI: 10.1161/HYPERTENSIONAHA.111.00006.
  12. Laurent S., Briet M., Boutouyrie P. Large and small artery cross-talk and recent morbidity-mortality trials in hypertension // Hypertension. – 2009; 54 (2): 388–92. DOI: 10.1161/HYPERTENSIONAHA.109.133116.
  13. de Rezende Mikael L., de Paiva A., Gomes M. et al. Vascular aging and arterial stiffness // Arq. Bras. Cardiol. – 2017; 109 (3): 253–8. DOI: 10.5935/abc.20170091.
  14. Cruickshank K., Riste L., Anderson S. et al. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? // Circulation. – 2002; 106 (16): 2085–90. DOI: 10.1161/01.CIR.0000033824.02722.
  15. Nillson P., Olsen M., Laurent S. Early vascular aging (EVA). New directions in cardiovascular protection / Elsevier Inc., 2015; 376 p.
  16. Dratva J., Probst-Hensch N., Schmidt-Trucksäss A. et al. Atherogenesis in youth – early consequence of adolescent smoking // Atherosclerosis. – 2013; 230 (2): 304–9. DOI: 10.1016/j.atherosclerosis.2013.08.004.
  17. Chung J., Lee Y., Kim J. et al. Reference Values for the Augmentation Index and Pulse Pressure in Apparently Healthy Korean Subjects // Korean. Circ. J. – 2010; 40: 165–71. DOI: 10.4070 / kcj.2010.40.4.165.
  18. Borghi C., Dormi A., D’Addato S. et al. Trends in blood pressure control and antihypertensive treatment in clinical practice: the Brisighella Heart // J. Hypertens. – 2004; 22 (9): 1707–16. DOI: 10.1097/00004872-200409000-0001.
  19. Kushnarenko N.N., Govorin A.V. Klinicheskoe znachenie endotelial'noj disfunktsii i sindroma insulinorezistentnosti u bol'nyh podagroj s arterial'noj gipertenziej // Ratsional'naja farmakoterapija v kardiologii. – 2013; 9 (5): 482–7 [Kushnarenko N.N., Govorin A.V. Clinical importance of endothelial dysfunction and insulin resistance syndrome in patients with gout associated with arterial hypertension // Rational Pharmacotherapy in Cardiology. – 2013; 9 (5): 482–7 (in Russ.)]. DOI: 10.20996/1819-6446-2013-9-5.
  20. Sadat U., Howarth S., Usman A. et al. Effect of low- and high-dose atorvastatin on carotid artery distensibility using carotid magnetic resonance imaing – a post-hoc sub group analysis of ATHEROMA (Atorvastatin Therapy: Effects On Reduction Of Macrophage Activity) Study // J. Atheroscler. Thromb. – 2013; 20 (1): 46–56. DOI: 10.5551/jat.12633.
  21. Kobalava Zh.D., Villeval'de S.V., Meraj I.A. i dr. Vlijanie sakubitril / valsartana na natrijurez, diurez i uroven' arterial'nogo davlenija u patsientov s arterial'noj gipertoniej // Ratsional'naja farmakoterapija v kardiologii. – 2017; 13 (3): 370–7 [Kobalava Z.D., Villevalde S.V., Meray I.A. et al. Effect of Sacubitril/Valsartan on Natriuresis, Diuresis and Blood Pressure in Hypertensive Patients // Rational Pharmacotherapy in Cardiology. – 2017; 13 (3): 370–7 (in Russ.)]. https://doi.org/10.20996/1819-6446-2017-13-3-370-377.
  22. Karpov Ju.A. Kak predupredit' rannee sosudistoe starenie u patsientov s arterial'noj gipertoniej? // Atmosfera. Novosti kardiologii. – 2016; 3: 2–10 [Karpov Yu.A. Kak predupredit’ rannee sosudistoe starenie u patsientov s arterial’noi gipertoniei? // Atmosfera. Novosti kardiologii. – 2016; 3: 2–10 (in Russ.)].
  23. Azevedo A., Prado A., Antonio R. et al. Matrix metalloproteinases are involved in cardiovascular diseases // Basic Clin. Pharmacol. Toxicol. – 2014; 115: 301–14. DOI: 10.1111/bcpt.12282.
  24. Oliver J., Dear J., Webb D. Clinical potential of combined organic nitrate and phosphodiesterase type 5 inhibitor in treatment-resistant hypertension // Hypertension. – 2010; 56 (1): 62–7. DOI: 10.1161/HYPERTENSIONAHA.109.147686.
  25. Stróżecki P., Kurowski R., Flisiński M. et al. Advanced glycation end products and arterial stiffness in patients with diabetic nephropathy and patients with chronic kidney disease without diabetes // Pol. Arch. Med. Wewn. – 2013; 123 (11): 609–16.